Literature DB >> 21280158

Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease.

Cynthia B Ripoll1, Mette Flaat, Jessica Klopf-Eiermann, Jeanne M Fisher-Perkins, Cynthia B Trygg, Brittni A Scruggs, Marjorie L McCants, Helen Paige Leonard, Amy F Lin, Shijia Zhang, Michelle E Eagle, Xavier Alvarez, Yu Teh Li, Su Chen Li, Jeffrey M Gimble, Bruce A Bunnell.   

Abstract

The twitcher mouse is an animal model of Krabbe's disease (KD), which is a neurodegenerative lysosomal storage disorder resulting from the absence of functional lysosomal enzyme galactocerebrosidase (GALC). This disease affects the central and peripheral nervous systems and in its most severe form results in death before the age of 2 in humans and approximately 30-40 days in mice. This study evaluates the effect of intracerebroventricular administration of mesenchymal stem cells derived from adipose tissue (ASCs) and bone marrow (BMSCs) on the pathology of KD. Subsequent to the intracerebroventricular injection of ASCs or BMSCs on postnatal day (PND) 3-4, body weight, lifespan, and neuromotor function were evaluated longitudinally beginning on PND15. At sacrifice, tissues were harvested for analysis of GALC activity, presence of myelin, infiltration of macrophages, microglial activation, inflammatory markers, and cellular persistence. Survival analysis curves indicate a statistically significant increase in lifespan in stem cell-treated twitcher mice as compared with control twitcher mice. Body weight and motor function were also improved compared with controls. The stem cells may mediate some of these benefits through an anti-inflammatory mechanism because the expression of numerous proinflammatory markers was downregulated at both transcriptional and translational levels. A marked decrease in the levels of macrophage infiltration and microglial activation was also noted. These data indicate that mesenchymal lineage stem cells are potent inhibitors of inflammation associated with KD progression and offer potential benefits as a component of a combination approach for in vivo treatment by reducing the levels of inflammation.
Copyright © 2010 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21280158      PMCID: PMC3412284          DOI: 10.1002/stem.555

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  60 in total

Review 1.  Inducible nitric oxide synthase: what difference does it make?

Authors:  C Nathan
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

2.  GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo.

Authors:  Xing-Li Meng; Jin-Song Shen; Kazuhiko Watabe; Toya Ohashi; Yoshikatsu Eto
Journal:  Mol Genet Metab       Date:  2005-01-24       Impact factor: 4.797

Review 3.  Role of nitric oxide in inflammation.

Authors:  F S Laroux; K P Pavlick; I N Hines; S Kawachi; H Harada; S Bharwani; J M Hoffman; M B Grisham
Journal:  Acta Physiol Scand       Date:  2001-09

4.  An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy.

Authors:  M Taniike; I Mohri; N Eguchi; D Irikura; Y Urade; S Okada; K Suzuki
Journal:  J Neuropathol Exp Neurol       Date:  1999-06       Impact factor: 3.685

5.  Substrate reduction intervention by L-cycloserine in twitcher mice (globoid cell leukodystrophy) on a B6;CAST/Ei background.

Authors:  Sangita Biswas; Homigol Biesiada; Todd D Williams; Steven M LeVine
Journal:  Neurosci Lett       Date:  2003-08-14       Impact factor: 3.046

6.  Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy.

Authors:  Juan T Borda; Xavier Alvarez; Mahesh Mohan; Marion S Ratterree; Kathrine Phillippi-Falkenstein; Andrew A Lackner; Bruce A Bunnell
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

7.  The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease).

Authors:  T Kobayashi; T Yamanaka; J M Jacobs; F Teixeira; K Suzuki
Journal:  Brain Res       Date:  1980-12-08       Impact factor: 3.252

8.  Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism.

Authors:  Farida Djouad; Louis-Marie Charbonnier; Carine Bouffi; Pascale Louis-Plence; Claire Bony; Florence Apparailly; Céline Cantos; Christian Jorgensen; Danièle Noël
Journal:  Stem Cells       Date:  2007-05-17       Impact factor: 6.277

9.  Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression.

Authors:  Guangwen Ren; Juanjuan Su; Liying Zhang; Xin Zhao; Weifang Ling; Andrew L'huillie; Jimin Zhang; Yongqing Lu; Arthur I Roberts; Weizhi Ji; Huatang Zhang; Arnold B Rabson; Yufang Shi
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

10.  Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.

Authors:  Kuriko Kagitani-Shimono; Ikuko Mohri; Yasushi Fujitani; Kinuko Suzuki; Keiichi Ozono; Yoshihiro Urade; Masako Taniike
Journal:  J Neuroinflammation       Date:  2005-04-06       Impact factor: 8.322

View more
  38 in total

1.  Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).

Authors:  Mark S Sands
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

2.  Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Lauren Shea; Xuntian Jiang; Daniel A Hunter; A Miguel Guzman; Adarsh S Reddy; Elizabeth Y Qin; Yedda Li; Steven J Gray; Daniel S Ory; Mark S Sands
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

Review 3.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 4.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

5.  Effect of vitamin D3 intake on the onset of disease in a murine model of human Krabbe disease.

Authors:  Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  J Neurosci Res       Date:  2014-09-19       Impact factor: 4.164

6.  Interleukin 6 mediates the therapeutic effects of adipose-derived stromal/stem cells in lipopolysaccharide-induced acute lung injury.

Authors:  Shijia Zhang; Svitlana D Danchuk; Ryan W Bonvillain; Beibei Xu; Brittni A Scruggs; Amy L Strong; Julie A Semon; Jeffrey M Gimble; Aline M Betancourt; Deborah E Sullivan; Bruce A Bunnell
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277

7.  Innate immune activation in the pathogenesis of a murine model of globoid cell leukodystrophy.

Authors:  Eric R Snook; Jeanne M Fisher-Perkins; Hope A Sansing; Kim M Lee; Xavier Alvarez; Andrew G MacLean; Karin E Peterson; Andrew A Lackner; Bruce A Bunnell
Journal:  Am J Pathol       Date:  2013-12-04       Impact factor: 4.307

8.  Oxidative stress as a therapeutic target in globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Elizabeth Y Qin; Adarsh S Reddy; Carole A Vogler; Mark S Sands
Journal:  Exp Neurol       Date:  2012-07-28       Impact factor: 5.330

9.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454

10.  Multipotent stromal cells alleviate inflammation, neuropathology, and symptoms associated with globoid cell leukodystrophy in the twitcher mouse.

Authors:  Brittni A Scruggs; Xiujuan Zhang; Annie C Bowles; Peter A Gold; Julie A Semon; Jeanne M Fisher-Perkins; Shijia Zhang; Ryan W Bonvillain; Leann Myers; Su Chen Li; Allan V Kalueff; Bruce A Bunnell
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.